Allarity Acquisition is a blank check company, or special purpose acquisition company (SPAC), formed to complete a merger, capital stock exchange, asset acquisition, or business combination. The company has no commercial operations or revenue and has not identified an acquisition target. Allarity Acquisition focuses primarily on acquiring businesses in the life sciences and biotechnology sectors globally, aiming to leverage management's industry and operational expertise. Under its business model, Allarity Acquisition raises capital through an IPO and places the proceeds into a trust account invested in U.S. Treasury bills or qualifying money market funds. The company has an 18-month window from the close of its offering to complete an initial business combination with a target possessing a fair market value of at least 80% of the trust assets. Public shareholders retain the right to redeem their shares for their pro-rata portion of the trust proceeds at the time of a transaction or upon liquidation if no deal is completed. The sponsor's economic return relies on founder shares and private warrants that only realize value upon the successful closing of an acquisition.